VEGFC Antibody - #DF7011

(5)   (5)  
Product: VEGFC Antibody
Catalog: DF7011
Description: Rabbit polyclonal antibody to VEGFC
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 46kDa; 47kD(Calculated).
Uniprot: P49767
RRID: AB_2838967

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(92%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(83%), Xenopus(92%)
Clonality:
Polyclonal
Specificity:
VEGFC Antibody detects endogenous levels of total VEGFC.
RRID:
AB_2838967
Cite Format: Affinity Biosciences Cat# DF7011, RRID:AB_2838967.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Flt 4L; Flt4 ligand; FLT4 ligand DHM; Flt4-L; Flt4L; Vascular endothelial growth factor C; Vascular endothelial growth factor related protein; Vascular endothelial growth factor-related protein; VEGF C; VEGF-C; Vegfc; VEGFC_HUMAN; VRP;

Immunogens

Immunogen:
Uniprot:

P49767(VEGFC_HUMAN) >>Visit HPA database.

Gene(ID):
VEGFC(7424)
Expression:
P49767 VEGFC_HUMAN:

Spleen, lymph node, thymus, appendix, bone marrow, heart, placenta, ovary, skeletal muscle, prostate, testis, colon and small intestine and fetal liver, lung and kidney, but not in peripheral blood lymphocyte.

Description:
The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor D.
Sequence:
MHLLGFFSVACSLLAAALLPGPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMTVLYPEYWKMYKCQLRKGGWQHNREQANLNSRTEETIKFAAAHYNTEILKSIDNEWRKTQCMPREVCIDVGKEFGVATNTFFKPPCVSVYRCGGCCNSEGLQCMNTSTSYLSKTLFEITVPLSQGPKPVTISFANHTSCRCMSKLDVYRQVHSIIRRSLPATLPQCQAANKTCPTNYMWNNHICRCLAQEDFMFSSDAGDDSTDGFHDICGPNKELDEETCQCVCRAGLRPASCGPHKELDRNSCQCVCKNKLFPSQCGANREFDENTCQCVCKRTCPRNQPLNPGKCACECTESPQKCLLKGKKFHHQTCSCYRRPCTNRQKACEPGFSYSEEVCRCVPSYWKRPQMS

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Horse
92
Xenopus
92
Chicken
83
Zebrafish
75
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P49767 As Substrate

Site PTM Type Enzyme
S101 Phosphorylation
T106 Phosphorylation
N175 N-Glycosylation
N205 N-Glycosylation

Research Backgrounds

Function:

Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors.

PTMs:

Undergoes a complex proteolytic maturation which generates a variety of processed secreted forms with increased activity toward VEGFR-3, but only the fully processed form could activate VEGFR-2. VEGF-C first form an antiparallel homodimer linked by disulfide bonds. Before secretion, a cleavage occurs between Arg-227 and Ser-228 producing a heterotetramer. The next extracellular step of the processing removes the N-terminal propeptide. Finally the mature VEGF-C is composed mostly of two VEGF homology domains (VHDs) bound by non-covalent interactions.

Subcellular Location:

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Spleen, lymph node, thymus, appendix, bone marrow, heart, placenta, ovary, skeletal muscle, prostate, testis, colon and small intestine and fetal liver, lung and kidney, but not in peripheral blood lymphocyte.

Subunit Structure:

Homodimer; non-covalent and antiparallel. Interacts with FLT4/VEGFR3; the interaction is required for FLT4/VEGFR3 homodimarization and activation.

Family&Domains:

Belongs to the PDGF/VEGF growth factor family.

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

References

1). TRAF6 regulates the signaling pathway influencing colorectal cancer function through ubiquitination mechanisms. Cancer Science, 2022 (PubMed: 35179811) [IF=5.7]

Application: WB    Species: human    Sample: SW480 and HCT116 cells

FIGURE 3|Effect of TRAF6 expression on NF-κB, pNF-κB, and VEGF-C expression in SW480 and HCT116 cells. (A, B) Western blotting analysis of NF-κB, pNF-κB, and VEGF-C expression in SW480 and HCT116 cells transfected with pCDH and pCDH-TRAF6, respectively.GAPDH served as a loading control.
2). BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo. MOLECULAR CARCINOGENESIS, 2017 (PubMed: 27770580) [IF=4.6]

Application: WB    Species: human    Sample: HepG2

Figure 6. Effect of BCL2L10 on its downstream gene expression profiles of human cancer pathway in HepG2 cells. (A) By human cancer pathway PCR array, ectopic expression of BCL2L10 up- or down-regulated several genes related to tumor proliferation, apoptosis, metastasis and angiogenesis. (B) Western blot was performed to confirm the downstream gene expression regulated by BCL2L10 in HepG2 cells. GAPDH was used as an internal control. (C) Schematic diagram of the molecular events for BCL2L10 function as a tumor suppressor through regulating cell cycle, proliferation, apoptosis metastasis and angiogenesis effectors.
3). REC8 promotes tumor migration, invasion and angiogenesis by targeting the PKA pathway in hepatocellular carcinoma. CLINICAL AND EXPERIMENTAL MEDICINE, 2021 (PubMed: 33677646) [IF=4.6]
4). Early pregnancy human decidua gamma/delta T cells exhibit tissue resident and specific functional characteristics. Molecular Human Reproduction, 2022 (PubMed: 35758607) [IF=4.0]

Application: IF/ICC    Species: Human    Sample: γδ T+ Cells

Figure 5.Identification of growth-factor secretion in human γδ T+ Cells. (A) qRT-PCR results from eight selected genes using RNA-sequencing. (B) Immunofluorescence analysis of growth-factor expression in sorted γδ T cells from early decidua (n = 5). (C) Immunofluorescence analysis of growth-factor expression in sorted γδ T cells from term decidua (n = 5). (D) Immunofluorescence analysis of growth-factor expression in sorted γδ T cells from peripheral blood mononuclear cells (PBMCs) (n = 5). (E) Immunofluorescence analysis of growth-factor expression in sorted γδ T cells from recurrent spontaneous abortion (RSA) patients (n = 5; scale bar, 50 μm). (F) qRT-PCR results regarding growth factors in sorted γδ T cells from RSA patients (n = 5). P-value was calculated by unpaired Student’s t-test.
5). Compared with High-intensity Interval Exercise, Moderate Intensity Constant Load Exercise is more effective in curbing the Growth and Metastasis of Lung Cancer. Journal of Cancer, 2022 (PubMed: 35371324) [IF=3.9]

Application: WB    Species: mouse    Sample: lung cancer

Figure 4. | The effect of exercise on lung cancer tissue angiogenesis and lymphangiogenesis.E, F. The effect of exercise on the expression of VEGFA in lung cancer tissues (n=6). E, G. The effect of exercise on the expression of VEGFC in lung cancer tissues (n=6). Note: &, && respectively represent a significant difference compared with the Saline group (P<0.05),(P<0.01).

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.